Last reviewed · How we verify
Viread
Viread is a Small molecule drug developed by Replicor Inc.. It is currently FDA-approved for Chronic type B viral hepatitis, Human immunodeficiency virus infection. Also known as: tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate 300mg.
Viread is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It works as a human immunodeficiency virus type 1 reverse transcriptase inhibitor, a type of small molecule inhibitor.
At a glance
| Generic name | Viread |
|---|---|
| Also known as | tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate 300mg |
| Sponsor | Replicor Inc. |
| Target | Gag-Pol polyprotein, Reverse transcriptase/RNaseH |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Chronic type B viral hepatitis
- Human immunodeficiency virus infection
Common side effects
- Rash
- Diarrhea
- Headache
- Pain
- Depression
- Asthenia
- Nausea
- Dizziness
- Abdominal pain
- Insomnia
- Pruritus
- Vomiting
Serious adverse events
- Bone Mineral Density decrease at lumbar spine
- Fasting cholesterol elevation
- Fasting triglyceride elevation
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers (PHASE2)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viread CI brief — competitive landscape report
- Viread updates RSS · CI watch RSS
- Replicor Inc. portfolio CI
Frequently asked questions about Viread
What is Viread?
What is Viread used for?
Who makes Viread?
Is Viread also known as anything else?
What development phase is Viread in?
What are the side effects of Viread?
What does Viread target?
Related
- Target: All drugs targeting Gag-Pol polyprotein, Reverse transcriptase/RNaseH
- Manufacturer: Replicor Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Chronic type B viral hepatitis
- Indication: Drugs for Human immunodeficiency virus infection
- Also known as: tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate 300mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing